Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study / Fenaux, P., Mufti, G.j., Hellstrom Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., Gore, S.d., Seymour, J.f., Bennett, J.m., Byrd, J., Backstrom, J., Zimmerman, L., Mckenzie, D., Beach, C., Silverman, L.r., Sacchi, S., et al.. - In: THE LANCET ONCOLOGY. - ISSN 1470-2045. - ELETTRONICO. - 10:(2009), pp. 223-232.
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
SANTINI, VALERIA;BOSI, ALBERTO;
2009
Abstract
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
| File | Dimensione | Formato | |
|---|---|---|---|
|
lancet.pdf
Accesso chiuso
Tipologia:
Versione finale referata (Postprint, Accepted manuscript)
Licenza:
Tutti i diritti riservati
Dimensione
231.52 kB
Formato
Adobe PDF
|
231.52 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
